MGI Tech Co., Ltd. (referred to as MGI) is committed to building core tools and technology to lead life science through intelligent innovation. With a focus on R&D, production and sales of DNA sequencing instruments, reagents, and related products, MGI provides real-time,
panoramic, and full-life-cycle equipment and systems for precision medicine, precision healthcare and other relevant areas.
MGI is a leading producer of clinical high-throughput gene sequencers, and
its multi-omics platforms include genetic sequencing, medical imaging, and laboratory automation.
Beijing GenePlus Technology Co., Ltd.
Beijing GenePlus Technology Co., Ltd (referred to as Gene+) was founded in 2015 and has since equipped next-generation sequencing (NGS) clinical laboratories and genetic institutes in Beijing, Suzhou and Shenzhen. Gene+ is a leading supplier for oncology and precision medicine in China. The Gene+ all-in-one solution utilizing MGI’s DNBSEQ platforms in Oncology has already been deployed in more than 30 key hospitals in China and is becoming a leader in the clinical application of NGS.
Together we provide expert oncology solutions to NGS users
The consistency of detected mutations between automated library construction samples by SP 100 and conventional library construction samples is 100%
Available assays include a Oncology 59-Gene Variant Assay and a Oncology Multi-Gene Variant Assay (1021-Gene) which have been validated on the DNBSEQ-G400 using HotMPS sequencing chemistry.
* This sequencer is only available in selected countries, and its software has been specially conﬁgured to be used in conjunction with MGI’s HotMPS sequencing reagents exclusively.
**This sequencing reagent is only available in selected countries.